Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu

项目摘要/摘要 急性淋巴细胞性白血病(ALL)是一种侵袭性的未成熟淋巴样肿瘤。在过去的几年里 几十年来，这些患者的疾病结局有了实质性的改善[3]。在某种程度上，这 改善是由于根据评估加强了对需要额外治疗的患者的识别 微小残留病(MRD)。目前，对MRD的评估是通过使用以下两种方法之一实现的： 特异性分子分析(主要在欧洲)和/或多参数流式细胞术(MPFC)， (通常在美国)。目前，以统一的方式执行这些办法是复杂和 很有挑战性。对MRD的个性化分子评估受到大型机构要求的限制 基础设施，因为每个患者的分子分析必须单独设计和验证。相反， 多参数流式细胞术难以标准化，质量参差不齐。虽然很明显MRD 对于指导针对患者的护理很重要，但目前的方法并不能持续地实现这一目标。 在一个初步项目中，43对治疗前和治疗后样本来自正在进行的T-ALL 儿童肿瘤学小组(COG)试验AALL0434[1]，我们证明了T细胞的高通量测序 受体基因重排增强了对极低水平MRD的检测，提高了敏感性和 多参数流式细胞术的特异性，而不需要复杂的机构基础设施 对最小残留疾病进行个性化的高灵敏度分子评估。我们发现，高吞吐量 测序可以在所有多参数流式细胞术确定疾病的患者中确定MRD。 然而，测序也允许以大约10倍的更高灵敏度检测MRD。我们有 自完成对99例B系急性淋巴细胞白血病患者的队列分析以来 摘自COG试验AALL0932(手稿正在准备中)。在这项研究中，我们还发现下一代 免疫球蛋白受体基因重排的测序可以提供对MRD的增强检测。 这些数据引发了几个问题。首先，这些疾病的临床特异性和敏感性是什么？ 发现了什么？第二，下一代测序在多大程度上适合在 临床实验室？在这个方案中，我们将高通量测序应用于敏感和全面的 评估B和T系ALL患者的MRD。

PROJECT SUMMARY/ABSTRACT Acute lymphoblastic leukemia (ALL) is an aggressive immature lymphoid neoplasm. Over the last couple of decades, there has been substantial improvement in disease outcomes for these patients [3]. In part, this improvement is due to enhanced identification of patients requiring additional therapy based on the assessment of minimal residual disease (MRD). Currently, assessment of MRD is achieved through the use of either patient- specific molecular assays (predominantly in Europe), and/or multi-parametric flow cytometry (mpFC), (commonly in the US). At present, implementation of these approaches in a uniform manner is complex and challenging. Individualized molecular assessment of MRD is limited by requirements for a large institutional infrastructure, as molecular assays for each patient must be individually-designed and validated. By contrast, multi-parametric flow cytometry is difficult to standardize, resulting in disparate quality. While it is clear that MRD is important for guiding patient-specific care, current approaches are not robust to achieve this goal consistently. In a preliminary project involving 43 paired pre- and post-treatment samples from an ongoing T-ALL Children's Oncology Group (COG) trial AALL0434 [1], we demonstrate that high-throughput sequencing of T-cell receptor gene rearrangements enhanced detection of very low-level MRD, improving upon the sensitivity and specificity of multi-parametric flow cytometry, without requiring the complex institutional infrastructure required to individualize high-sensitivity molecular evaluation for minimal residual disease. We found that high-throughput sequencing could identify MRD in all patients in whom multi-parametric flow cytometry identified disease. However, sequencing also permitted detection of MRD at a higher sensitivity of approximately 10-fold. We have since completed analysis of another cohort of 99 patients with B-lineage acute lymphoblastic leukemia derived from COG trial AALL0932 (manuscript in preparation). In this study, we also found that next-generation sequencing of immunoglobulin receptor gene rearrangements could provide enhanced detection of MRD. Several questions are raised by these data. First, what is the clinical specificity and sensitivity of these findings? Second, to what extent is next-generation sequencing suitable for routine implementation in the clinical laboratory? In this proposal, we apply high-throughput sequencing to sensitively and comprehensively assess MRD in patients with B- and T-lineage ALL.